InVivo Therapeutics Holdings (FRA:04I) Interest Expense : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. InVivo Therapeutics Holdings's interest expense for the three months ended in Sep. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. InVivo Therapeutics Holdings's Operating Income for the three months ended in Sep. 2023 was € -2.65 Mil. InVivo Therapeutics Holdings's Interest Expense for the three months ended in Sep. 2023 was € 0.00 Mil. InVivo Therapeutics Holdings has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

InVivo Therapeutics Holdings Interest Expense Historical Data

The historical data trend for InVivo Therapeutics Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Interest Expense Chart

InVivo Therapeutics Holdings Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

InVivo Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

InVivo Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

InVivo Therapeutics Holdings (FRA:04I) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

InVivo Therapeutics Holdings's Interest Expense for the three months ended in Sep. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was €-2.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was €0.00 Mil.

InVivo Therapeutics Holdings's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

InVivo Therapeutics Holdings had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. InVivo Therapeutics Holdings Corp has enough cash to cover all of its debt. Its financial situation is stable.

InVivo Therapeutics Holdings (FRA:04I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NVIV:USA

Address

One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.invivotherapeutics.com

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines